Do not give subtype-specific recommendations. Instead, create a structured checklist of questions for our...

Questions to Ask Your Oncology & Transplant Team: Post-Induction Decision Planning

I can see you're navigating a complex post-induction situation with your daughter's AML. Rather than recommending specific treatments, I've organized the key questions you should ask your team to clarify the clinical picture and ensure you're making informed decisions together.

---

1) UNDERSTANDING THE CURRENT DISEASE STATUS

Why this matters: Your daughter's marrow shows PCR non-detectable disease (which is excellent), but the hypocellular marrow and inconclusive MRD create uncertainty about what's actually happening. Your team needs to help you understand what these findings mean together.

Questions to ask:

• "Can you explain what 'hypocellular marrow' means for my daughter's prognosis right now? Does this change how you interpret the PCR non-detectable result?"
• "The MRD testing was inconclusive due to low cellularity. When you repeat the marrow aspirate, what specific markers or methods will you use to get a clearer picture?"
• "Is the hypocellularity expected at this point post-induction, or does it suggest something about how her marrow is recovering?"
• "What percentage of blast cells would you expect to see in a normal post-induction marrow at this timepoint?"
• "How will you distinguish between 'good response with slow marrow recovery' versus 'incomplete response' when the repeat marrow comes back?"

What to document: Ask for copies of the pathology report from the post-induction marrow. Specifically note:

• Exact cellularity percentage
• Blast percentage
• Any dysplastic changes noted
• Which MRD markers were tested and why results were inconclusive

---

2) CONSOLIDATION TREATMENT OPTIONS & RATIONALE

Why this matters: According to NCCN Guidelines for Patients, consolidation therapy after induction is tailored based on disease response and risk factors. Your team should explain why they're considering specific options for your daughter's situation.

Questions to ask:

• "Based on my daughter's specific AML subtype (CBFA2T3::GLIS2) and her induction response, what consolidation options are you considering, and why?"
• "If FLAG-IDA + Venetoclax is being discussed, what is the evidence for this combination in pediatric AML with her specific genetics?"
• "What are the goals of consolidation therapy—is it to achieve deeper remission, prepare for transplant, or both?"
• "How many cycles of consolidation are typically recommended for her risk group?"
• "What would success look like after consolidation? What test results would you be looking for?"

What to clarify: Ask your team to explain:

• How her specific biomarker (CBFA2T3::GLIS2) influences treatment choice
• Whether consolidation is being used as a bridge to transplant or as definitive therapy
• What the expected toxicity profile is for any proposed regimen

---

3) MINIMAL RESIDUAL DISEASE (MRD) MONITORING PLAN

Why this matters: MRD monitoring guides treatment intensity and transplant decisions. You need a clear plan for how and when MRD will be assessed going forward.

Questions to ask:

• "What is the plan for repeat MRD testing? When will it happen, and which methods will be used?"
• "What MRD result would be considered 'good response' versus 'concerning' at each timepoint?"
• "If repeat marrow shows MRD-positive disease, how would that change the treatment plan?"
• "How often will MRD be monitored during consolidation and after?"
• "Are there any clinical trials specifically for CBFA2T3::GLIS2 AML that use MRD-directed therapy?"

What to understand: According to NCCN Guidelines, MRD status (positive vs. negative) is a key factor in deciding consolidation intensity and transplant timing. Ask your team to explain what threshold they use for their decision-making.

---

4) HEMATOPOIETIC CELL TRANSPLANT (HCT) PLANNING

Why this matters: Transplant is often considered in pediatric AML consolidation. You need clarity on whether it's planned, when, and what factors might change that decision.

Questions to ask:

• "Is HCT part of the planned consolidation strategy for my daughter? Why or why not?"
• "If transplant is planned, what is the timeline? Would it happen after one cycle of consolidation or multiple cycles?"
• "What donor options are being explored (matched sibling, matched unrelated donor, haploidentical)?"
• "Has HLA typing been done? When will you know about donor availability?"
• "What would need to happen (in terms of disease response or other factors) to change the transplant plan?"
• "What are the risks and benefits of transplant versus continuing chemotherapy alone for her specific situation?"

What to clarify: Ask about:

• Whether transplant is being considered as consolidation (standard approach) or only if disease doesn't respond well
• The timeline for HLA typing and donor search
• What "preparatory regimen" (conditioning) would be used if transplant proceeds

---

5) VENETOCLAX-CONTAINING REGIMENS: EVIDENCE & SAFETY

Why this matters: You've asked about venetoclax-containing approaches. This is an important conversation to have with your team about evidence, safety in pediatrics, and how it fits into your daughter's plan.

Questions to ask:

• "What is the evidence for venetoclax in pediatric AML, particularly in my daughter's age group and with her specific subtype?"
• "If venetoclax is being considered, would it be part of consolidation, or is it being reserved for relapse/refractory disease?"
• "What are the known side effects of venetoclax in children, and how would they be monitored?"
• "Are there any clinical trials using venetoclax-containing regimens that my daughter might be eligible for?"
• "How does venetoclax fit into the overall treatment plan—is it meant to deepen remission, reduce transplant intensity, or something else?"

What to understand: Venetoclax is increasingly used in adult AML but has more limited pediatric data. Your team should be transparent about whether they're using it based on strong evidence or as part of a clinical trial/investigational approach.

---

6) CLINICAL TRIALS & CAR-T CELL THERAPY OPTIONS

Why this matters: You mentioned CAR-T and trials as backup discussions. Understanding what's available and when these might be relevant is important for your planning.

Questions to ask:

• "Are there any open clinical trials for pediatric CBFA2T3::GLIS2 AML that my daughter might be eligible for?"
• "What is the role of CAR-T cell therapy in pediatric AML? Would it be considered now, or only if disease relapses?"
• "Are there any CAR-T trials specifically for AML that we should know about?"
• "If my daughter's disease doesn't respond as expected to consolidation, what would the next steps be?"
• "How do you decide between intensifying chemotherapy, pursuing transplant, or enrolling in a trial?"

What to clarify: Ask your team to:

• Provide specific trial names and contact information if applicable
• Explain the eligibility criteria for any trials being discussed
• Discuss timing—when would CAR-T or other experimental approaches become relevant

---

7) MANAGING THE HYPOCELLULAR MARROW & RECOVERY

Why this matters: The hypocellular marrow affects both disease assessment and treatment planning. You need to understand what's normal recovery versus concerning.

Questions to ask:

• "What does 'hypocellular marrow' mean, and is this expected after induction therapy?"
• "How long does marrow recovery typically take in pediatric AML patients?"
• "Are there any supportive care measures that can help marrow recovery (growth factors, transfusions, etc.)?"
• "Will the hypocellularity affect the timing of consolidation therapy?"
• "What blood counts or other signs would indicate that the marrow is recovering appropriately?"

What to monitor: Ask about:

• Expected timeline for marrow cellularity to normalize
• What blood counts (hemoglobin, platelets, neutrophils) you should expect to see improve
• Any signs of infection or bleeding that would require intervention

---

8) TREATMENT SIDE EFFECTS & SUPPORTIVE CARE

Why this matters: Consolidation therapy can be intensive. Understanding what to expect helps you prepare and recognize when to contact your team.

**Questions